We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SM

News List

Blueprint Announces EMA Validation of Type II Variation Marketing Authorization Application for AYVAKYT americanpharmaceuticalreview
March 09, 2021
Blueprint Medicines announced the European Medicines Agency (EMA) has validated the company's Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of advanced systemic mastocytosis (SM).
Blueprint eyes quick filing for GIST drug avapritinib pharmaphorum
December 13, 2018
Blueprint Medicines has new data for its lead cancer drug avapritinib in gastrointestinal stromal tumours (GIST) that set it on course for regulatory filings – and a close race to market with rival Deciphera.
Blueprint Announces Updated Results from Ongoing Avapritinib Trial americanpharmaceuticalreview
December 04, 2018
Blueprint Medicines announced updated results for the Phase 1 EXPLORER clinical trial of avapritinib, a potent and highly selective inhibitor of D816V mutant KIT.....